Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders as those individuals who (1) access child pornography due to impulse without any specific sexual interest in children; (2) access child pornography to satisfy sexual fantasies but do not commit contact sex offenses; (3) make and handout child pornography just for financial gain and benefit; and (4) use the Internet to facilitate contact sex offenses. Sexual offenders create many challenges for treatment providers probation officers, and even just regular people in their community. Sexual offenders create challenges because the treatment providers and probation officers have to decide what care is best and what limitations are necessary for that specific individual